d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Use of the partial NMDA receptor agonist d-Cycloserine (DCS) to increase extinction to feared cues among anxious adults has shown mixed, although overall positive effects. Few studies have extended this effect to youth and none have addressed young people with broad-based anxiety such as separation anxiety, social anxiety, or generalised anxiety. In the current trial 51 children and adolescents with diagnosed anxiety disorders, aged 7–14 years received four sessions of graduated, experimenter-led, in vivo exposure to a hierarchy of feared cues relevant to their primary fear. They were randomly allocated to receive either 50 mg of DCS or a matched placebo capsule in a fully double-blind design. Both groups showed large reductions across sessions in their primary fear according to both parent and child report, but there were no significant differences between conditions at any session. The results are consistent with most studies to date of DCS-augmented exposure in young people.

LanguageEnglish
Pages225-231
Number of pages7
JournalBehaviour Research and Therapy
Volume87
DOIs
Publication statusPublished - Dec 2016

Fingerprint

Cycloserine
Anxiety Disorders
Anxiety
Fear
Cues
Separation Anxiety
N-Methyl-D-Aspartate Receptors
Capsules
Placebos

Keywords

  • d-Cycloserine
  • Anxiety
  • Youth
  • in vivo exposure
  • Child anxiety
  • Treatment

Cite this

@article{7ae4940907204de8aed6aa949aa58250,
title = "d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders",
abstract = "Use of the partial NMDA receptor agonist d-Cycloserine (DCS) to increase extinction to feared cues among anxious adults has shown mixed, although overall positive effects. Few studies have extended this effect to youth and none have addressed young people with broad-based anxiety such as separation anxiety, social anxiety, or generalised anxiety. In the current trial 51 children and adolescents with diagnosed anxiety disorders, aged 7–14 years received four sessions of graduated, experimenter-led, in vivo exposure to a hierarchy of feared cues relevant to their primary fear. They were randomly allocated to receive either 50 mg of DCS or a matched placebo capsule in a fully double-blind design. Both groups showed large reductions across sessions in their primary fear according to both parent and child report, but there were no significant differences between conditions at any session. The results are consistent with most studies to date of DCS-augmented exposure in young people.",
keywords = "d-Cycloserine, Anxiety, Youth, in vivo exposure, Child anxiety, Treatment",
author = "Rapee, {Ronald M.} and Jones, {Michael P.} and Hudson, {Jennifer L.} and Malhi, {Gin S.} and Lyneham, {Heidi J.} and Schneider, {Sophie C.}",
year = "2016",
month = "12",
doi = "10.1016/j.brat.2016.10.004",
language = "English",
volume = "87",
pages = "225--231",
journal = "Behaviour Research and Therapy",
issn = "0005-7967",
publisher = "Pergamon-Elsevier Science",

}

d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders. / Rapee, Ronald M.; Jones, Michael P.; Hudson, Jennifer L.; Malhi, Gin S.; Lyneham, Heidi J.; Schneider, Sophie C.

In: Behaviour Research and Therapy, Vol. 87, 12.2016, p. 225-231.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders

AU - Rapee, Ronald M.

AU - Jones, Michael P.

AU - Hudson, Jennifer L.

AU - Malhi, Gin S.

AU - Lyneham, Heidi J.

AU - Schneider, Sophie C.

PY - 2016/12

Y1 - 2016/12

N2 - Use of the partial NMDA receptor agonist d-Cycloserine (DCS) to increase extinction to feared cues among anxious adults has shown mixed, although overall positive effects. Few studies have extended this effect to youth and none have addressed young people with broad-based anxiety such as separation anxiety, social anxiety, or generalised anxiety. In the current trial 51 children and adolescents with diagnosed anxiety disorders, aged 7–14 years received four sessions of graduated, experimenter-led, in vivo exposure to a hierarchy of feared cues relevant to their primary fear. They were randomly allocated to receive either 50 mg of DCS or a matched placebo capsule in a fully double-blind design. Both groups showed large reductions across sessions in their primary fear according to both parent and child report, but there were no significant differences between conditions at any session. The results are consistent with most studies to date of DCS-augmented exposure in young people.

AB - Use of the partial NMDA receptor agonist d-Cycloserine (DCS) to increase extinction to feared cues among anxious adults has shown mixed, although overall positive effects. Few studies have extended this effect to youth and none have addressed young people with broad-based anxiety such as separation anxiety, social anxiety, or generalised anxiety. In the current trial 51 children and adolescents with diagnosed anxiety disorders, aged 7–14 years received four sessions of graduated, experimenter-led, in vivo exposure to a hierarchy of feared cues relevant to their primary fear. They were randomly allocated to receive either 50 mg of DCS or a matched placebo capsule in a fully double-blind design. Both groups showed large reductions across sessions in their primary fear according to both parent and child report, but there were no significant differences between conditions at any session. The results are consistent with most studies to date of DCS-augmented exposure in young people.

KW - d-Cycloserine

KW - Anxiety

KW - Youth

KW - in vivo exposure

KW - Child anxiety

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85008658928&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/arc/DP1095162

U2 - 10.1016/j.brat.2016.10.004

DO - 10.1016/j.brat.2016.10.004

M3 - Article

VL - 87

SP - 225

EP - 231

JO - Behaviour Research and Therapy

T2 - Behaviour Research and Therapy

JF - Behaviour Research and Therapy

SN - 0005-7967

ER -